메뉴 건너뛰기




Volumn 30, Issue 3, 2014, Pages 359-367

Congenital absence of nitric oxide synthase 3 potentiates cardiac dysfunction and reduces survival in doxorubicin- and trastuzumab-mediated cardiomyopathy

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; BLOTTING, WESTERN; CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; DOXORUBICIN; ECHOCARDIOGRAPHY; FEMALE; HEART VENTRICLES; MICE; MICE, INBRED C57BL; MYOCARDIUM; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84894242784     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.11.013     Document Type: Article
Times cited : (18)

References (46)
  • 1
    • 0034004583 scopus 로고    scopus 로고
    • Assessing the risk of breast cancer
    • Armstrong K., Eisen A., Weber B. Assessing the risk of breast cancer. N Engl J Med 2000, 342:564-571.
    • (2000) N Engl J Med , vol.342 , pp. 564-571
    • Armstrong, K.1    Eisen, A.2    Weber, B.3
  • 2
    • 0035888074 scopus 로고    scopus 로고
    • Estimating the world cancer burden: Globocan 2000
    • Parkin D.M., Bray F., Ferlay J., Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001, 94:153-156.
    • (2001) Int J Cancer , vol.94 , pp. 153-156
    • Parkin, D.M.1    Bray, F.2    Ferlay, J.3    Pisani, P.4
  • 3
    • 2342591455 scopus 로고    scopus 로고
    • The discovery of receptor tyrosine kinases: targets for cancer therapy
    • Gschwind A., Fischer O.M., Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004, 4:361-370.
    • (2004) Nat Rev Cancer , vol.4 , pp. 361-370
    • Gschwind, A.1    Fischer, O.M.2    Ullrich, A.3
  • 4
    • 0032915392 scopus 로고    scopus 로고
    • Epidermal growth factor receptors: critical mediators of multiple receptor pathways
    • Hackel P.O., Zwick E., Prenzel N., Ullrich A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 1999, 11:184-189.
    • (1999) Curr Opin Cell Biol , vol.11 , pp. 184-189
    • Hackel, P.O.1    Zwick, E.2    Prenzel, N.3    Ullrich, A.4
  • 5
    • 0034638917 scopus 로고    scopus 로고
    • Overexpression of ErbB2 in cancer and ErbB2-targeting strategies
    • Yu D., Hung M.C. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000, 19:6115-6121.
    • (2000) Oncogene , vol.19 , pp. 6115-6121
    • Yu, D.1    Hung, M.C.2
  • 6
    • 37049183697 scopus 로고
    • Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
    • Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
    • (1987) Science , vol.235 , pp. 177-182
    • Slamon, D.J.1    Clark, G.M.2    Wong, S.G.3
  • 7
    • 0032563825 scopus 로고    scopus 로고
    • Doxorubicin-induced cardiomyopathy
    • Singal P.K., Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998, 339:900-905.
    • (1998) N Engl J Med , vol.339 , pp. 900-905
    • Singal, P.K.1    Iliskovic, N.2
  • 8
    • 0015849162 scopus 로고
    • A clinicopathologic analysis of adriamycin cardiotoxicity
    • Lefrak E.A., Pitha J., Rosenheim S., Gottlieb J.A. A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer 1973, 32:302-314.
    • (1973) Cancer , vol.32 , pp. 302-314
    • Lefrak, E.A.1    Pitha, J.2    Rosenheim, S.3    Gottlieb, J.A.4
  • 9
    • 0034820943 scopus 로고    scopus 로고
    • Anthracycline-induced cardiomyopathy
    • Keefe D.L. Anthracycline-induced cardiomyopathy. Semin Oncol 2001, 28(4 suppl 11):2-7.
    • (2001) Semin Oncol , vol.28 , Issue.4 SUPPL. 11 , pp. 2-7
    • Keefe, D.L.1
  • 10
    • 34248573600 scopus 로고    scopus 로고
    • Managing cardiotoxicity in anthracycline-treated breast cancers
    • Ng R., Green M.D. Managing cardiotoxicity in anthracycline-treated breast cancers. Expert Opin Drug Saf 2007, 6:315-321.
    • (2007) Expert Opin Drug Saf , vol.6 , pp. 315-321
    • Ng, R.1    Green, M.D.2
  • 12
    • 0026610881 scopus 로고
    • Humanization of an anti-p185HER2 antibody for human cancer therapy
    • Carter P., Presta L., Gorman C.M., et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 1992, 89:4285-4289.
    • (1992) Proc Natl Acad Sci U S A , vol.89 , pp. 4285-4289
    • Carter, P.1    Presta, L.2    Gorman, C.M.3
  • 13
    • 0036467826 scopus 로고    scopus 로고
    • Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
    • Vogel C.L., Cobleigh M.A., Tripathy D., et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726.
    • (2002) J Clin Oncol , vol.20 , pp. 719-726
    • Vogel, C.L.1    Cobleigh, M.A.2    Tripathy, D.3
  • 14
    • 0034183463 scopus 로고    scopus 로고
    • New strategies for managing metastatic breast cancer
    • Olin J.J., Muss H.B. New strategies for managing metastatic breast cancer. Oncology (Williston Park) 2000, 14:629-641.
    • (2000) Oncology (Williston Park) , vol.14 , pp. 629-641
    • Olin, J.J.1    Muss, H.B.2
  • 15
    • 0035869407 scopus 로고    scopus 로고
    • Concurrent administration of anti-HER2 monoclonal antibody and first-line chemotherapy for HER2-overexpressing metastatic breast cancer. A phase III, multinational, randomized control trial
    • Slamon D.J., Leyland-Jones B., Shak S., et al. Concurrent administration of anti-HER2 monoclonal antibody and first-line chemotherapy for HER2-overexpressing metastatic breast cancer. A phase III, multinational, randomized control trial. N Engl J Med 2001, 344:783-792.
    • (2001) N Engl J Med , vol.344 , pp. 783-792
    • Slamon, D.J.1    Leyland-Jones, B.2    Shak, S.3
  • 16
    • 26844503270 scopus 로고    scopus 로고
    • Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
    • Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
    • (2005) N Engl J Med , vol.353 , pp. 1659-1672
    • Piccart-Gebhart, M.J.1    Procter, M.2    Leyland-Jones, B.3
  • 17
    • 26844536978 scopus 로고    scopus 로고
    • Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    • Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
    • (2005) N Engl J Med , vol.353 , pp. 1673-1684
    • Romond, E.H.1    Perez, E.A.2    Bryant, J.3
  • 18
    • 43849094005 scopus 로고    scopus 로고
    • Cardiotoxicity profile of Trastuzumab
    • Ewer S.M., Ewer M.S. Cardiotoxicity profile of Trastuzumab. Drug Saf 2008, 31:459-467.
    • (2008) Drug Saf , vol.31 , pp. 459-467
    • Ewer, S.M.1    Ewer, M.S.2
  • 19
    • 58149250715 scopus 로고    scopus 로고
    • Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278)
    • Guarneri V., Frassoldati A., Bruzzi P., et al. Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278). Clin Breast Cancer 2008, 8:453-456.
    • (2008) Clin Breast Cancer , vol.8 , pp. 453-456
    • Guarneri, V.1    Frassoldati, A.2    Bruzzi, P.3
  • 20
    • 33845914783 scopus 로고    scopus 로고
    • 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
    • Smith I., Procter M., Gelber R.D., et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007, 369:29-36.
    • (2007) Lancet , vol.369 , pp. 29-36
    • Smith, I.1    Procter, M.2    Gelber, R.D.3
  • 21
    • 33745615786 scopus 로고    scopus 로고
    • Herceptin (trastuzumab): adjuvant and neoadjuvant trials
    • Yaal-Hahoshen N., Safra T. Herceptin (trastuzumab): adjuvant and neoadjuvant trials. Isr Med Assoc J 2006, 8:416-421.
    • (2006) Isr Med Assoc J , vol.8 , pp. 416-421
    • Yaal-Hahoshen, N.1    Safra, T.2
  • 22
    • 33344478381 scopus 로고    scopus 로고
    • Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
    • Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354:809-820.
    • (2006) N Engl J Med , vol.354 , pp. 809-820
    • Joensuu, H.1    Kellokumpu-Lehtinen, P.L.2    Bono, P.3
  • 23
    • 68949121146 scopus 로고    scopus 로고
    • Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study
    • Wadhwa D., Fallah-Rad N., Grenier D., et al. Trastuzumab mediated cardiotoxicity in the setting of adjuvant chemotherapy for breast cancer: a retrospective study. Breast Cancer Res Treat 2009, 117:357-364.
    • (2009) Breast Cancer Res Treat , vol.117 , pp. 357-364
    • Wadhwa, D.1    Fallah-Rad, N.2    Grenier, D.3
  • 24
    • 77955294878 scopus 로고    scopus 로고
    • The role of 3D echocardiography in breast cancer: comparison with 2D echocardiography, MUGA and cardiac MRI
    • Walker J.R., Bhullar N., Fallah-Rad N., et al. The role of 3D echocardiography in breast cancer: comparison with 2D echocardiography, MUGA and cardiac MRI. J Clin Oncol 2010, 28:3429-3436.
    • (2010) J Clin Oncol , vol.28 , pp. 3429-3436
    • Walker, J.R.1    Bhullar, N.2    Fallah-Rad, N.3
  • 25
    • 79957576807 scopus 로고    scopus 로고
    • The utility of cardiac biomarkers, tissue velocity and strain imaging and cardiac MRI in predicting early left ventricular dysfunction in patients with HER-2 positive breast cancer treated with adjuvant trastuzumab therapy
    • Fallah-Rad N., Walker J.R., Wassef A., et al. The utility of cardiac biomarkers, tissue velocity and strain imaging and cardiac MRI in predicting early left ventricular dysfunction in patients with HER-2 positive breast cancer treated with adjuvant trastuzumab therapy. J Am Coll Cardiol 2011, 57:2263-2270.
    • (2011) J Am Coll Cardiol , vol.57 , pp. 2263-2270
    • Fallah-Rad, N.1    Walker, J.R.2    Wassef, A.3
  • 26
    • 0032796535 scopus 로고    scopus 로고
    • Mechanisms of beneficial effects of probucol in adriamycin cardiomyopathy
    • Iliskovic N., Hasinoff B.B., Malisza K.L., et al. Mechanisms of beneficial effects of probucol in adriamycin cardiomyopathy. Mol Cell Biochem 1999, 196:43-49.
    • (1999) Mol Cell Biochem , vol.196 , pp. 43-49
    • Iliskovic, N.1    Hasinoff, B.B.2    Malisza, K.L.3
  • 27
    • 0343554684 scopus 로고    scopus 로고
    • Doxorubicin-induced acute changes in cytotoxic aldehydes, antioxidant status and cardiac function in the rat
    • Luo X., Evrovsky Y., Cole D., et al. Doxorubicin-induced acute changes in cytotoxic aldehydes, antioxidant status and cardiac function in the rat. Biochem Biophys Acta 1997, 1360:45-52.
    • (1997) Biochem Biophys Acta , vol.1360 , pp. 45-52
    • Luo, X.1    Evrovsky, Y.2    Cole, D.3
  • 28
    • 0030855953 scopus 로고    scopus 로고
    • Adriamycin cardiomyopathy: pathophysiology and prevention
    • Singal P.K., Iliskovic N., Li T., Kumar D. Adriamycin cardiomyopathy: pathophysiology and prevention. FASEB J 1997, 11:931-936.
    • (1997) FASEB J , vol.11 , pp. 931-936
    • Singal, P.K.1    Iliskovic, N.2    Li, T.3    Kumar, D.4
  • 29
    • 9644310269 scopus 로고    scopus 로고
    • Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy
    • Grazette L.P., Boecker W., Matsui T., et al. Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 2004, 44:2231-2238.
    • (2004) J Am Coll Cardiol , vol.44 , pp. 2231-2238
    • Grazette, L.P.1    Boecker, W.2    Matsui, T.3
  • 30
    • 59049093631 scopus 로고    scopus 로고
    • Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways
    • Gordon L.I., Burke M.A., Singh A.T., et al. Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem 2009, 284:2080-2087.
    • (2009) J Biol Chem , vol.284 , pp. 2080-2087
    • Gordon, L.I.1    Burke, M.A.2    Singh, A.T.3
  • 31
    • 34548403111 scopus 로고    scopus 로고
    • Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin
    • Neilan T.G., Blake S.L., Ichinose F., et al. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation 2007, 116:506-514.
    • (2007) Circulation , vol.116 , pp. 506-514
    • Neilan, T.G.1    Blake, S.L.2    Ichinose, F.3
  • 32
    • 79956368032 scopus 로고    scopus 로고
    • The cardioprotective role of probucol against anthracycline and trastuzumab mediated cardiotoxicity
    • Walker J.R., Sharma A., Lytwyn M., et al. The cardioprotective role of probucol against anthracycline and trastuzumab mediated cardiotoxicity. J Am Soc Echocardiogr 2011, 24:699-705.
    • (2011) J Am Soc Echocardiogr , vol.24 , pp. 699-705
    • Walker, J.R.1    Sharma, A.2    Lytwyn, M.3
  • 33
    • 74549224505 scopus 로고    scopus 로고
    • The art of healing broken hearts in breast cancer: trastuzumab and heart failure
    • Walker J.R., Singal P.K., Jassal D.S. The art of healing broken hearts in breast cancer: trastuzumab and heart failure. Exp Clin Cardiol 2009, 14:e62-e67.
    • (2009) Exp Clin Cardiol , vol.14
    • Walker, J.R.1    Singal, P.K.2    Jassal, D.S.3
  • 34
    • 8144229686 scopus 로고    scopus 로고
    • Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice
    • Nozaki N., Shishido T., Takeishi Y., Kubota I. Modulation of doxorubicin-induced cardiac dysfunction in toll-like receptor-2-knockout mice. Circulation 2004, 110:2869-2874.
    • (2004) Circulation , vol.110 , pp. 2869-2874
    • Nozaki, N.1    Shishido, T.2    Takeishi, Y.3    Kubota, I.4
  • 35
    • 58349097915 scopus 로고    scopus 로고
    • Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice
    • Riad A., Bien S., Westermann D., et al. Pretreatment with statin attenuates the cardiotoxicity of doxorubicin in mice. Cancer Res 2009, 69:695-699.
    • (2009) Cancer Res , vol.69 , pp. 695-699
    • Riad, A.1    Bien, S.2    Westermann, D.3
  • 36
    • 63249107117 scopus 로고    scopus 로고
    • Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy
    • Jassal D.S., Han S.Y., Hans C., et al. Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy. J Am Soc Echocardiogr 2009, 22:418-424.
    • (2009) J Am Soc Echocardiogr , vol.22 , pp. 418-424
    • Jassal, D.S.1    Han, S.Y.2    Hans, C.3
  • 37
    • 70349317477 scopus 로고    scopus 로고
    • Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents
    • Riccio G., Esposito G., Leoncini E., et al. Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents. FASEB J 2009, 23:3171-3178.
    • (2009) FASEB J , vol.23 , pp. 3171-3178
    • Riccio, G.1    Esposito, G.2    Leoncini, E.3
  • 38
    • 80053995420 scopus 로고    scopus 로고
    • Novel toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice
    • Yousif N.G., Al-Amran F.G. Novel toll-like receptor-4 deficiency attenuates trastuzumab (Herceptin) induced cardiac injury in mice. BMC Cardiovasc Disord 2011, 11:62.
    • (2011) BMC Cardiovasc Disord , vol.11 , pp. 62
    • Yousif, N.G.1    Al-Amran, F.G.2
  • 39
    • 84863726300 scopus 로고    scopus 로고
    • Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors
    • Fedele C., Riccio G., Coppola C., et al. Comparison of preclinical cardiotoxic effects of different ErbB2 inhibitors. Breast Cancer Res Treat 2012, 133:511-521.
    • (2012) Breast Cancer Res Treat , vol.133 , pp. 511-521
    • Fedele, C.1    Riccio, G.2    Coppola, C.3
  • 40
    • 21144436077 scopus 로고    scopus 로고
    • Quantitative assessment of regional myocardial function in mice by tissue Doppler imaging: comparison with hemodynamics and sonomicrometry
    • Sebag I.A., Handschumacher M.D., Ichinose F., et al. Quantitative assessment of regional myocardial function in mice by tissue Doppler imaging: comparison with hemodynamics and sonomicrometry. Circulation 2005, 111:2611-2616.
    • (2005) Circulation , vol.111 , pp. 2611-2616
    • Sebag, I.A.1    Handschumacher, M.D.2    Ichinose, F.3
  • 41
    • 70449158340 scopus 로고
    • A simple method for the isolation and purification of total lipides from animal tissues
    • Folch J., Lees M., Sloane Stanley G. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 1957, 226:497-509.
    • (1957) J Biol Chem , vol.226 , pp. 497-509
    • Folch, J.1    Lees, M.2    Sloane Stanley, G.3
  • 42
    • 84869074308 scopus 로고    scopus 로고
    • Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions
    • van Dijk R.A., Kolodgie F., Ravandi A., et al. Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. J Lipid Res 2012, 53:2773-2790.
    • (2012) J Lipid Res , vol.53 , pp. 2773-2790
    • van Dijk, R.A.1    Kolodgie, F.2    Ravandi, A.3
  • 43
    • 0042858394 scopus 로고    scopus 로고
    • Oxidized phospholipids in minimally modified low density lipoprotein induce apoptotic signaling via activation of acid sphingomyelinase in arterial smooth muscle cells
    • Loidl A., Sevcsik E., Riesenhuber G., Deigner H.P., Hermetter A. Oxidized phospholipids in minimally modified low density lipoprotein induce apoptotic signaling via activation of acid sphingomyelinase in arterial smooth muscle cells. J Biol Chem 2003, 278:32921-32928.
    • (2003) J Biol Chem , vol.278 , pp. 32921-32928
    • Loidl, A.1    Sevcsik, E.2    Riesenhuber, G.3    Deigner, H.P.4    Hermetter, A.5
  • 44
    • 22444445619 scopus 로고    scopus 로고
    • Deletion of the eNOS gene has a greater impact on the pulmonary circulation of male than female mice
    • Miller A.A., Hislop A.A., Vallance P.J., Haworth S.G. Deletion of the eNOS gene has a greater impact on the pulmonary circulation of male than female mice. Am J Physiol Lung Cell Mol Physiol 2005, 289:L299-L306.
    • (2005) Am J Physiol Lung Cell Mol Physiol , vol.289
    • Miller, A.A.1    Hislop, A.A.2    Vallance, P.J.3    Haworth, S.G.4
  • 45
    • 78650679530 scopus 로고    scopus 로고
    • Distinct role and location of the endothelial isoform of nitric oxide synthase 3 in regulating platelet aggregation in males and females in vivo
    • Moore C., Sanz-Rosa D., Emerson M. Distinct role and location of the endothelial isoform of nitric oxide synthase 3 in regulating platelet aggregation in males and females in vivo. Eur J Pharmacol 2011, 651:152-158.
    • (2011) Eur J Pharmacol , vol.651 , pp. 152-158
    • Moore, C.1    Sanz-Rosa, D.2    Emerson, M.3
  • 46
    • 69349095566 scopus 로고    scopus 로고
    • Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial
    • Choi J.Y., Barlow W.E., Albain K.S., et al. Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin Cancer Res 2009, 15:5258-5266.
    • (2009) Clin Cancer Res , vol.15 , pp. 5258-5266
    • Choi, J.Y.1    Barlow, W.E.2    Albain, K.S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.